echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Compete with Chia Tai Tianqing and Yangzijiang for another Chengdu pharmaceutical company to disrupt antidepressants

    Compete with Chia Tai Tianqing and Yangzijiang for another Chengdu pharmaceutical company to disrupt antidepressants

    • Last Update: 2020-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network September 23rd, September 22nd, CDE official website shows that Chengdu Kanghong Pharmaceuticals' hydrobromobromohitine tablet imitation 4 categories of listing applications were accepted.
    meters of intranet data show that in 2019, China's public medical institutions terminal voxelstin tablet sales of more than 30 million yuan, production enterprises only Lingbei one.
    Prior to this, the product Yangzijiang to imitation 3 categories, Zhengda Tianqing Pharmaceutical Group and Chengdu Beit Pharmaceuticals to copy 4 categories of submitted applications for listing, in the review and approval (in the drug review center).
    hydrobromobromoxitin tablets are used to treat depression in adults.
    November 2017, the hydrobrominate vulcanization tablets (commodity name: Xinda Yue) developed by The Danish company Lingbei were approved for listing by the State Drug Administration.
    source: MiNet one-click search Minet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of vulcan tablets, although only more than 30 million yuan, but the growth rate is staggering, up more than 700% year-on-year, manufacturers only Lingbei.
    Source: MED2.0 China Drug Review Database, before the product Yangzijiang to copy 3 categories, Zhengda Tianqing Pharmaceutical Group and Chengdu Beit Pharmaceuticals to copy 4 categories to submit a listing application in the review and approval (in the drug review center).
    from the date of the contractor, Yangzijiang's time is the earliest.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.